Akebia Therapeutics Inc. (NASDAQ:AKBA) went down by -1.98% from its latest closing price compared to the recent 1-year high of $13.71. The company’s stock price has collected -0.40% of loss in the last five trading sessions. Press Release reported on 10/02/20 that Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Is It Worth Investing in Akebia Therapeutics Inc. (NASDAQ :AKBA) Right Now?
Plus, the 36-month beta value for AKBA is at 1.79. Opinions of the stock are interesting as 5 analysts out of 8 who provided ratings for Akebia Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 3 rated it as “hold,” and 0 as “sell.”
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The average price from analysts is $6.86. AKBA currently public float of 134.72M and currently shorts hold a 6.80% ratio of that float. Today, the average trading volume of AKBA was 4.82M shares.
AKBA’s Market Performance
AKBA stocks went down by -0.40% for the week, with a monthly drop of -75.30% and a quarterly performance of -81.09%, while its annual performance rate touched -35.76%. The volatility ratio for the week stands at 5.71% while the volatility levels for the past 30 days are set at 8.13% for Akebia Therapeutics Inc.. The simple moving average for the period of the last 20 days is -5.83% for AKBA stocks with a simple moving average of -71.98% for the last 200 days.
Analysts’ Opinion of AKBA
Many brokerage firms have already submitted their reports for AKBA stocks, with Needham repeating the rating for AKBA by listing it as a “Buy.” The predicted price for AKBA in the upcoming period, according to Needham is $15 based on the research report published on November 14th of the previous year 2019.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see AKBA reach a price target of $17, previously predicting the price at $19. The rating they have provided for AKBA stocks is “Buy” according to the report published on August 06th, 2019.
H.C. Wainwright gave a rating of “Buy” to AKBA, setting the target price at $21 in the report published on July 11th of the previous year.
AKBA Trading at -67.18% from the 50-Day Moving Average
After a stumble in the market that brought AKBA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.98% of loss for the given period.
Volatility was left at 8.13%, however, over the last 30 days, the volatility rate increased by 5.71%, as shares sank -6.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -79.38% lower at present.
During the last 5 trading sessions, AKBA fell by -0.40%, which changed the moving average for the period of 200-days by -62.00% in comparison to the 20-day moving average, which settled at $2.61. In addition, Akebia Therapeutics Inc. saw -60.92% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at AKBA starting from GOWEN MAXINE, who sale 4,567 shares at the price of $12.05 back on Jun 08. After this action, GOWEN MAXINE now owns 24,133 shares of Akebia Therapeutics Inc., valued at $55,032 using the latest closing price.
GILMAN STEVEN C, the Director of Akebia Therapeutics Inc., sale 4,567 shares at $12.08 during a trade that took place back on Jun 08, which means that GILMAN STEVEN C is holding 38,864 shares at $55,169 based on the most recent closing price.
Stock Fundamentals for AKBA
Current profitability levels for the company are sitting at:
- -85.46 for the present operating margin
- +56.61 for the gross margin
The net margin for Akebia Therapeutics Inc. stands at -83.48. The total capital return value is set at -49.62, while invested capital returns managed to touch -49.32. Equity return is now at value -94.70, with -49.80 for asset returns.
Based on Akebia Therapeutics Inc. (AKBA), the company’s capital structure generated 27.44 points at debt to equity in total, while total debt to capital is 21.53. Total debt to assets is 14.05, with long-term debt to equity ratio resting at 26.18. Finally, the long-term debt to capital ratio is 20.54.
When we switch over and look at the enterrpise to sales, we see a ratio of 2.12, with the company’s debt to enterprise value settled at 0.15. The receivables turnover for the company is 12.07 and the total asset turnover is 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.49.